Help
RSS
API
Feed
Maltego
Contact
Domain > www.kadcyla.com
×
More information on this domain is in
AlienVault OTX
Is this malicious?
Yes
No
DNS Resolutions
Date
IP Address
2019-09-28
52.9.196.166
(
ClassC
)
2024-04-30
104.18.1.83
(
ClassC
)
2024-05-04
172.64.152.111
(
ClassC
)
2024-08-01
104.18.19.111
(
ClassC
)
2024-12-28
104.18.18.111
(
ClassC
)
Port 80
HTTP/1.1 301 Moved PermanentlyDate: Tue, 30 Apr 2024 20:57:55 GMTContent-Type: text/htmlContent-Length: 167Connection: keep-aliveCache-Control: max-age3600Expires: Tue, 30 Apr 2024 21:57:55 GMTLocatio html>head>title>301 Moved Permanently/title>/head>body>center>h1>301 Moved Permanently/h1>/center>hr>center>cloudflare/center>/body>/html>
Port 443
HTTP/1.1 200 OKDate: Tue, 30 Apr 2024 20:57:55 GMTContent-Type: text/html; charsetUTF-8Transfer-Encoding: chunkedConnection: keep-alivevary: Accept-EncodingCF-Cache-Status: DYNAMICSet-Cookie: __cf_bmC !DOCTYPE HTML>html langen-US> head> meta charsetUTF-8/> title>KADCYLA® (ado-trastuzumab emtansine) in HER2+ Breast Cancer/title> meta namedescription contentLearn about KADCYLA® (ado-trastuzumab emtansine), a treatment for certain patients with early or metastatic HER2+ breast cancer. See Full Safety and Boxed Warnings for more information./> meta nametemplate contentflexible-page/> meta nameviewport contentwidthdevice-width, initial-scale1/> link relcanonical hrefhttps://www.kadcyla.com/index.html/> meta propertyog:site_name contentkadcyla/> meta propertyog:type contentwebsite/> meta propertyog:locale contenten_US/> meta propertyog:title contentKADCYLA® (ado-trastuzumab emtansine) in HER2+ Breast Cancer/> meta propertyog:description contentLearn about KADCYLA® (ado-trastuzumab emtansine), a treatment for certain patients with early or metastatic HER2+ breast cancer. See Full Safety and Boxed Warnings for more information./> meta propertyog:url contenthttps://www.kadcyla.com/index.html/> meta propertyog:image contenthttps://www.kadcyla.com/content/dam/gene/kadcyla/patient/logos/Kadcyla.genecoreimg.1200.png/> meta propertyog:image:type contentimage/png/> meta propertyog:image:width content420/> meta propertyog:image:height content185/> meta propertyog:image:alt contentKADCYLA® (ado-trastuzumab emtansine)/> meta nametwitter:card contentsummary_large_image/> link relicon typeimage/x-icon href/content/dam/gene/kadcyla/favicon.ico/> link relshortcut icon typeimage/x-icon href/content/dam/gene/kadcyla/favicon.ico/> link hrefhttps://fonts.googleapis.com/css2?familyOpen+Sans:ital,wght@0,400;0,700;1,400;1,700&displayswap relstylesheet/> script typetext/plain classoptanon-category-C0002> window.NREUM||(NREUM{}),__nr_requirefunction(t,n,e){function r(e){if(!ne){var one{exports:{}};te0.call(o.exports,function(n){var ote1n;return r(o||n)},o,o.exports)}return ne.exports}if(functiontypeof __nr_require)return __nr_req
View on OTX
|
View on ThreatMiner
Please enable JavaScript to view the
comments powered by Disqus.
Data with thanks to
AlienVault OTX
,
VirusTotal
,
Malwr
and
others
. [
Sitemap
]